Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 24, No 28 (October 1), 2006: pp. 4539-4544
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.4859

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Govindan, R.
Right arrow Articles by Piccirillo, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Govindan, R.
Right arrow Articles by Piccirillo, J.
Related Articles
Right arrowRelated Editorial

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, William Read, Ryan Tierney, Anna Vlahiotis, Edward L. Spitznagel, Jay Piccirillo

From the Departments of Internal Medicine, Otolaryngology-Head and Neck Surgery, Psychiatry, and Mathematics, Washington University School of Medicine, St Louis, MO; and the University of California-San Diego, San Diego, CA

Address reprint requests to Ramaswamy Govindan, MD, Division of Oncology, Washington University School of Medicine, 4960 Children's Place, Suite 108, St Louis, MO 63110; e-mail: rgovinda{at}im.wustl.edu

PURPOSE: Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years.

METHODS: We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance.

RESULTS: The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period.

CONCLUSION: Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • Changing Face of Small-Cell Lung Cancer: Real and Artifact
    David S. Ettinger and Joseph Aisner
    JCO 2006 24: 4526-4527 [Full Text]


This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al.
A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial
J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. J. Weiss, L. T. Bemis, E. Nakajima, M. Sugita, D. K. Birks, W. A. Robinson, M. Varella-Garcia, P. A. Bunn Jr, J. Haney, B. A. Helfrich, et al.
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
Ann. Onc., February 27, 2008; (2008) mdn006v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. P. Belani, S. Ramalingam, M. C. Perry, R. V. LaRocca, D. Rinaldi, P. S. Gable, and W. J. Tester
Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 20, 2008; 26(3): 468 - 473.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
J. Clin. Oncol., January 1, 2008; 26(1): 60 - 65.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. M. Arnold, L. Seymour, M. Smylie, K. Ding, Y. Ung, B. Findlay, C. W. Lee, M. Djurfeldt, M. Whitehead, P. Ellis, et al.
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20
J. Clin. Oncol., September 20, 2007; 25(27): 4278 - 4284.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. A. Socinski and J. A. Bogart
Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy
J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry
Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?
Oncologist, September 1, 2007; 12(9): 1096 - 1104.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, P. Postmus, L. Collette, E. Musat, S. Senan, et al.
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
N. Engl. J. Med., August 16, 2007; 357(7): 664 - 672.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. Schairer, M. Hisada, B. E. Chen, L. M. Brown, R. Howard, S. D. Fossa, M. Gail, and L. B. Travis
Comparative Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers
J Natl Cancer Inst, August 15, 2007; 99(16): 1248 - 1256.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. R. Eckardt, J. von Pawel, J.-L. Pujol, Z. Papai, E. Quoix, A. Ardizzoni, R. Poulin, A. J. Preston, G. Dane, and G. Ross
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 2086 - 2092.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. A. Garcia and B. I. Rini
Recent Progress in the Management of Advanced Renal Cell Carcinoma
CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. S. Ettinger and J. Aisner
Changing Face of Small-Cell Lung Cancer: Real and Artifact
J. Clin. Oncol., October 1, 2006; 24(28): 4526 - 4527.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online